Newsbenzinga
OPKO Biologics Doses First Patient In Its Phase 1/2a Clinical Study Of OPK-8801001 To Treat Acromegaly
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…